Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.

Automated summary

This review explains the role of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumorigenesis and metastasis of ovarian cancer. Clinical studies have shown promising results using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, including ovarian cancer. Combining HGF/c-MET targeted therapy with chemotherapy drugs could be an effective strategy for treating ovarian cancer.